The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Drug Safety Progressives – The Rise of the Pharmacovigilante

Posted by Jim Davis on Feb 2, 2017 11:00:00 AM

The United States is a polarized place right now. Democrats vs. Republicans. Liberals vs. Conservatives. President Trump vs. the world. The divide runs deep and battle lines have been drawn. And while there is no escaping this highly publicized political chasm, there is another fight being played out in the shadows… The Drug Safety Progressives vs. the Drug Safety Conservatives.

I was at the DIA Pharmacovigilance and Risk Management conference last week, fittingly taking place in Washington D.C right after the inauguration and the women’s march.  The division was obvious.

Read More

Topics: Drug Safety, DIA

Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes

Posted by Brian Overstreet on Jan 26, 2017 10:30:00 AM

We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry.  Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally. 

Read More

Topics: Drug Safety, Health Outcomes

Real-Time Drug Safety Analysis with Evidex Alerts

Posted by Bob Kyle on Jan 20, 2017 10:30:00 AM

This week we launched Evidex Alerts, a new feature that provides our clients with real-time updates on the latest impactful drug safety news. This is a project that our development and analyst teams have worked on diligently for the last three months, and I am excited to announce that it became a reality this week. 

Read More

Topics: Drug Safety, Clinical Trials, Evidex

Will 2017 Be The Year of Drug Safety?

Posted by Brian Overstreet on Jan 12, 2017 1:53:43 PM

On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system.  Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist.  And I’m willing to say it.”  Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all.  Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me.  If you haven’t watched the report, I’d urge you to do so (link is here).

Read More

Topics: Drug Safety

Working Toward a Cure: The Foundation for Sarcoidosis Research

Posted by Jim Davis on Jan 5, 2017 11:00:00 AM

In November 2016, I was honored to be asked to join the Board of Directors of the Foundation for Sarcoidosis Research (FSR). The foundation began in 1999 as a grassroots organization, and now has expanded their efforts and impact to become the leader in supporting sarcoidosis research. I'm looking forward to using my experiences both as a sarcoidosis patient and in drug safety to contribute to the mission. Please visit www.stopsarcoidosis.org for more information. 

I originally wrote the post below for the FSR blog. The original can be seen here

Read More

Topics: Drug Safety, sarcoidoisis

Looking Ahead - Drug Safety in 2017

Posted by Brian Overstreet on Dec 16, 2016 11:00:00 AM

As 2016 winds down, am I the only one who feels exhausted? 

Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.

Read More

Topics: Drug Safety, Clinical Evidence, Evidex

Establish Drug Safety Benchmarks with an Evidence Aggregation Platform

Posted by Jim Davis on Oct 27, 2016 11:00:00 AM

 

Drug safety is often equated with post-marketing pharmacovigilance, something that is required by manufacturers only after their drug is approved. But when drug safety data are presented in an evidence aggregation platform there are very strong use cases in pharmaceutical competitive intelligence, health economics and outcomes (HEOR), and R&D. An evidence aggregation platform takes multiple sources of information and boils it down into actionable insight. That insight often has use cases that span all departments and can meet the demands of various priorities. 

Read More

Topics: Drug Safety, Evidex, benchmarks, real world data, evidence aggregation platform, clinical trial results, adverse events

Drug Safety Snail Mail. Really?

Posted by Brian Overstreet on Sep 1, 2016 10:30:00 AM

Last week the U.S. Surgeon General Vivek Murthy sent a letter to every doctor in the U.S. to warn them of the dangers of opioid addiction.  While certainly well intentioned, I have to ask - in this age of technology, is this the best we can do?  Why not fax or, even better, send a Western Union cable?

Read More

Topics: Drug Safety, opioids, healthcare

Express Scripts’ 2017 Exclusions – Analysis Using Real World Data

Posted by Jim Davis on Aug 2, 2016 4:30:28 PM

It has become tradition at Advera Health to look closely at the annual formulary exclusions that the large payers such as Express Scripts introduce every August. Using our safety scoring and costing algorithms we are able to quickly provide a top-line view into the effects of their decisions. 

Read More

Topics: Drug Safety, Drug Formulary, Express Scrips, RxCost

The Long Run

Posted by Brian Overstreet on Jan 26, 2016 10:30:00 AM

It’s been a tough few weeks for music fans with the deaths of David Bowie to liver cancer and Glen Frey to complications from rheumatoid arthritis and ulcerative colitis.  These are just two of the millions of people worldwide suffering from these diseases, but I’m sure I’m not the only one who felt a sense of loss from the passing of these two men.  Both profoundly influenced my adolescence and early adulthood through their music. 

In the days following the news of Frey’s death, news stories emerged sourcing his longtime manager Irving Azoff and medical professionals unrelated to his treatment that assigned some degree of blame on Frey’s death to the medications he was taking to treat his conditions.

Read More

Topics: Drug Safety, RxScore, Formulary

Subscribe to Email Updates